Avenue Therapeutics Inc (ATXI)
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for neurologic diseases. Its pipeline includes AJ201, which is being studied in a Phase 1b/2a clinical trial for spinal and bulbar muscular atrophy, intravenous tramadol for post-operative acute pain, and BAER-101 for epilepsy and panic disorders. Incorporated in 2015 and headquartered in Bay Harbor Islands, Florida, the company operates as a subsidiary of Fortress Biotech, Inc. Avenue Therapeutics’ common stock trades on OTC Markets under the symbol ATXI.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ATXI
|
$0.44
|
-11.3% Downside
|
Fair
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 13, 2026
|
2.8x
|
1.647 M
|
-367.006 K
|
0.0%
|
86.5%
|
-181.3
|
49.8%
|
